Fight cancer, but how? Chemotherapy kills cancer cells but also healthy cells. The use of our immune cells (Tcells) could allow a more targeted attack of cancer cells but are limited.

Genetic engineering makes it possible to transform our Tcells into an army of superkiller cells (CART) which reinjected can destroy a tumor.

Clinical trials have shown that, but this is just the beginning of a new era where reprogrammed cells can become super sophisticated drugs. A medical revolution begins! André Choulika, Ph.D., is one of the founders of Cellectis and served as Chief Executive Officer since the company's inception in 1999. He is Chairman of the Board of Directors since 2011 and President of Calyxt since August 2010. From 1997 to 1999, Dr. Choulika worked as a postdoctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nucleasebased genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from the HEC (Challenge +). This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx